Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)

Crinetics Pharmaceuticals (CRNX) has 3 years of Equity Income data on record, last reported at -$470000.0 in Q1 2024.

  • For Q1 2024, Equity Income changed N/A year-over-year to -$470000.0; the TTM value through Dec 2024 reached -$470000.0, up 90.96%, while the annual FY2024 figure was -$470000.0, 90.96% up from the prior year.
  • Equity Income reached -$470000.0 in Q1 2024 per CRNX's latest filing, up from -$4.2 million in the prior quarter.
  • Across five years, Equity Income topped out at -$470000.0 in Q1 2024 and bottomed at -$4.2 million in Q4 2023.
  • Average Equity Income over 3 years is -$1.7 million, with a median of -$1.0 million recorded in 2022.